This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Report: Biopharma And Medical Device Companies Beat Historic Investment Returns

Stocks in this article: SIVB

SANTA CLARA, Calif., July 30, 2014 /PRNewswire/ -- Silicon Valley Bank, the bank of the global innovation economy, released a study today that examines the merger, acquisition and IPO activity of private, venture-backed biopharma and medical device companies.  According to the annual report based on 2013 data, venture investment in healthcare saw the biggest potential returns since SVB started tracking the data in 2005.

Silicon Valley Bank logo.

"2013 was the year of the IPO.  Built on solid healthcare M&A activity over the last few years, the venture industry continued to see momentum and a burst of IPO activity that provided spectacular potential returns for investors," said Jonathan Norris, Managing Director with SVB and author of the report. "We predict healthy access to capital in 2014 and into 2015.  While IPO activity is cooling in these sectors, we expect to see an increase in big exit M&A activity in the second half of this year."

Silicon Valley Bank works with 50 percent of healthcare-focused venture capital firms and venture-backed companies nationwide and specializes in biopharma, medical device and healthcare services.

In 2013, a year in which the number of healthcare IPOs tripled, public market enthusiasm helped stabilize venture investment and fundraising overall. Last year also saw increased valuations of mergers and acquisitions in the sector.  As the study notes, the climate for healthcare-related IPOs is slowing; however, the current and balanced financing ecosystem is continuing to prime the innovation pump and encourage smooth capital flow to keep the industry humming.

Based on an analysis of IPOs and private merger or acquisition transactions of venture capital-backed companies between 2005 and 2013, Silicon Valley Bank finds

  • Healthcare IPOs tripled in 2013, leading to a record potential IPO/big exit return of $12.5 billion — a nine-year high
  • Healthcare venture fundraising exceeded $3.5 billion in each of the past three years, a healthy level for innovation
  • Large biopharma companies are essentially outsourcing early-stage R&D by investing heavily in young venture-backed companies and as significant investors into Healthcare Venture Funds
  • Among big exit M&A (defined as private, venture-backed M&A with upfront payments of $75 million or higher for biopharma deals and $50 million or higher for device deals):
    • The average total deal value for biopharma big exit M&A was $549 million in 2013, the highest level since SVB started tracking the data in 2005, and it represents a 10 percent increase over 2012.
    • Device big exit M&A activity declined, but the average total deal value was $231 million in 2013, a three-year high, which represents a 42 percent increase over 2012.
  • Bucking convention in the device sector, FDA approval was not necessary for big exits
  • Healthcare venture will continue to see strong returns

The study also reveals the growing interest by corporate venture groups in healthcare.  Corporate venture was part of the investor syndicate in 35% of all biotech Series A equity financings in 2013, up from 30% in 2012.  Additionally, there are positive signs of corporate interest in early-stage medical device companies. 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs